A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS

Clinical trial NCT02488408 · COMPLETED

Trial details

NCT number: NCT02488408
Sponsor: BerGenBio ASA
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Myelodysplastic Syndromes

Start date: 2014-10-22
Primary completion: 2022-06-08
Enrollment: 122

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.